Immuto Scientific

Executive Summary

Immuto Scientific is a San Diego-based private biotech company pioneering a novel target discovery approach that focuses on Surface Protein Conformations (SPCs)—disease-specific protein structures invisible to traditional methods. Conventional proteomics often misses critical pathological differences in protein shape, leaving many therapeutic opportunities unexploited. By targeting SPCs, Immuto aims to unlock a new class of drug targets for diagnostics and therapeutics. Founded in 2018, the company is at an early stage with no disclosed funding, valuation, or commercial products. Its innovation addresses a key bottleneck in drug discovery: the identification of structurally distinct disease markers. If successful, Immuto's platform could enable precision treatments for conditions where current target discovery falls short. The company's progress is limited by its early stage and lack of public data, but its focus on conformational epitopes represents a potentially high-impact niche in proteomics.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement40% success
• Q2 2027First Research Partnership with Pharma30% success
• Q1 2027Peer-Reviewed Publication on SPC Platform Validation50% success